EcoDrugPlus

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSSAUG00010023478
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSSAUG00010019383
Gene Symbol: HTR7
3 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSSAUG00010027493
Gene Symbol: LOC115568713
3 Cross references
477 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSAUG00010007098
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSAUG00010024811
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSAUG00010004966
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSSAUG00010019771
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSSAUG00010019847
Gene Symbol: AKT1
3 Cross references
195 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSSAUG00010022421
Gene Symbol: ALK
2 Cross references
193 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSSAUG00010011993
Gene Symbol: ABCC1
3 Cross references
201 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 8

Ensembl ID : ENSSAUG00010003560
Gene Symbol: ABCC8
1 Cross references
225 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 9

Ensembl ID : ENSSAUG00010023046
Gene Symbol: ABCC9
1 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).